U.S. markets closed
  • S&P 500

    4,688.67
    -12.23 (-0.26%)
     
  • Dow 30

    35,931.05
    -211.17 (-0.58%)
     
  • Nasdaq

    15,921.57
    -52.28 (-0.33%)
     
  • Russell 2000

    2,377.01
    -28.02 (-1.16%)
     
  • Crude Oil

    78.20
    -0.16 (-0.20%)
     
  • Gold

    1,871.50
    +1.30 (+0.07%)
     
  • Silver

    25.18
    +0.01 (+0.05%)
     
  • EUR/USD

    1.1326
    +0.0003 (+0.02%)
     
  • 10-Yr Bond

    1.6040
    -0.0300 (-1.84%)
     
  • GBP/USD

    1.3489
    -0.0003 (-0.02%)
     
  • USD/JPY

    114.1330
    -0.0070 (-0.01%)
     
  • BTC-USD

    60,551.46
    +802.27 (+1.34%)
     
  • CMC Crypto 200

    1,489.80
    +11.14 (+0.75%)
     
  • FTSE 100

    7,291.20
    -35.77 (-0.49%)
     
  • Nikkei 225

    29,597.88
    -90.45 (-0.30%)
     

CNBC's Final Trades: Fiserv, ResMed, Monster Beverage And This Semiconductor Company

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

On CNBC’s “Halftime Report Final Trades,” Jenny Harrington of Gilman Hill Asset Management said Fiserv Inc (NASDAQ: FISV) belongs to its growth portfolio.

The stock is trading at 16 times earnings and has the potential for 15% earnings growth ahead, Harrington said. The stock is “wildly oversold,” she added.

Another trader in the show named Qualcomm, Inc. (NASDAQ: QCOM), saying that its upcoming analyst day should be a catalyst.

Joseph Terranova of Virtus Investment Partners cited ResMed Inc. (NYSE: RMD) as a top pick, noting the positives as being a San Diego-based medical equipment company with a focus on sleep disorder.

Pete Najarian named Monster Beverage Corp (NASDAQ: MNST). “I see some call buying in there and I think this stock’s going higher,” he commented.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.